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BACKGROUND: Faecal occult blood tests (FOBTs) are used for colorectal cancer (CRC) screening. We aimed to assess the sensitivity of
an immunochemical FOBT for detecting advanced colorectal neoplasia in the left vs the right colon and to explore reasons for
potential differences in site-specific test performance.
METHODS: We prospectively measured faecal occult blood levels by a quantitative immunochemical FOBT (RIDASCREEN) in 2310
average-risk subjects undergoing screening colonoscopy. We compared diagnostic performance for subjects with left- vs right-sided
advanced neoplasia, as well as patient characteristics and adenoma characteristics that have been suggested to impact faecal
haemoglobin levels.
RESULTS: Sensitivities for subjects with left- vs right-sided advanced neoplasia were 33% (95% confidence interval (CI), 26–41%) and
20% (CI, 11–31%) (P¼0.04) at a specificity of 95% (overall sensitivity: 29%) and the areas under the receiver-operating
characteristics curve were 0.71 (CI, 0.69–0.72) and 0.60 (CI, 0.58–0.63), respectively. Pedunculated shape was strikingly more
common in participants with left- vs right-sided advanced neoplasia (47% vs 14%). In logistic regression analyses adjusted for site,
pedunculated shape was statistically significantly associated with test sensitivity (P¼0.04).
CONCLUSIONS: The immunochemical FOBT in our study was more sensitive for detecting subjects with left- vs right-sided advanced
colorectal neoplasia. Our findings may stimulate further diagnostic research in the field as well as modelling analyses to estimate the
potential effect of site-specific test performance on the effectiveness of annual or biennial FOBT-based screening programmes, in
particular with respect to protection from right-sided CRC.
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With 41 million new cases and 4500000 deaths per year
worldwide, colorectal cancer (CRC) is the third most common
cancer and the fourth most common cancer cause of death globally
(Parkin et al, 2005). Owing to its slow development from
removable precursor lesions (i.e., adenomas) and early cancer
stages with good prognosis, screening for CRC has been shown to
reduce the mortality of the disease (Mandel et al, 1993; Hardcastle
et al, 1996; Jorgensen et al, 2002; Heresbach et al, 2006). However,
there is a growing body of evidence suggesting that screening
colonoscopy, when performed in the community setting, is more
effective in protecting from neoplasia in the left colon and rectum
than in protecting from neoplasia in the right colon (Brenner et al,
2007, 2010b; Lakoff et al, 2008; Baxter et al, 2009). While different
reasons for the poorer protective effect of colonoscopy in the right
compared with the left colon are discussed (Ransohoff, 2009), it is
an important question whether the sensitivity of the most common
non-invasive screening tool for CRC, faecal occult blood testing
(FOBT), also differs for left- vs right-sided neoplasia. Given that
positive FOBT results are typically followed up by colonoscopy, a
lower sensitivity both of FOBT and colonoscopy for right-sided
neoplasia would make the potential of FOBT screening to protect
from right-sided CRC even worse.
From a theoretical point of view, there are at least two
arguments that support a higher sensitivity of FOBT for left sided
than for right-sided neoplasia. First, degradation of haemoglobin
during colon passage could favour the detection of left-sided
neoplasia (Rockey, 2010). Second, due to differences in stool
consistency, blood may be more homogeneously distributed when
originating from the right side and more on the surface when
originating from the left side, which would also favour the
detection of left-sided neoplasia.
Empirical evidence from screening studies with colonoscopic
follow-up of all participants is crucial to precisely estimate site-
specific test performance. To date, such evidence is limited. A large
study investigated an immunochemical FOBT in 420000 average-
risk subjects and showed a sensitivity of 31 and 16% for left- and
right-sided advanced neoplasia, respectively, at a specificity of 95%
(Morikawa et al, 2005). For guaiac-based FOBT, a similar
difference in site-specific test performance was observed by
Ahlquist et al (2008) in a study with about 2500 average-risk
subjects, reporting a sensitivity of 13 and 7% (Hemoccult) and of
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s27 and 11% (Hemoccult SENSA) for left- and right-sided advanced
colorectal neoplasia, respectively. However, neither study provided
further information on the subgroups with left- and right-sided
advanced neoplasia, and it thus remains unclear whether other
factors with potential impact on diagnostic performance of FOBT,
such as gender, non-steroidal anti-inflammatory (NSAID) drug use
or adenoma characteristics, such as size, pedunculated shape or
plural occurrence (Ciatto et al, 2007; Morikawa et al, 2007; Levi
et al, 2009; Rozen et al, 2009), were differentially distributed
between the subgroups.
The aim of this study was to address site-specific performance of
a quantitative immunochemical FOBT in a large screening study
and to explore factors that could explain potential differences in
sensitivity for left- and right-sided advanced neoplasia.
MATERIALS AND METHODS
Study design, data and sample collection
We used data from the Begleitende Evaluierung innovativer
Testverfahren zur Darmkrebsfru ¨herkennung (BliTz) study to
evaluate the site-specific diagnostic performance of an immuno-
chemical FOBT. The BliTz study is an ongoing prospective
screening study conducted in southwestern Germany aimed to
comparatively evaluate novel tests for early detection of CRC. For
the present analyses, we included patients recruited from January
2006 to November 2009. The details of the study design have
already been published (Hundt et al, 2009; Haug et al, 2010;
Brenner et al, 2010a).
Briefly, the study includes participants of screening colonoscopy –
a procedure that the German health care system has offered
since October 2002 to average-risk persons 55 years or older. Only
experienced endoscopists (internists/gastroenterologists or sur-
geons with pertinent certified specialisations) having conducted
at least 200 colonoscopies and at least 50 polypectomies under
supervision in the preceding two calendar years are permitted to
conduct screening colonoscopies. Requirements for maintenance
of permission include conduction of at least 200 colonoscopies and
at least 10 polypectomies per year. Quality control measures also
include the image documentation of complete colonoscopy.
Persons undergoing screening colonoscopy typically present at
the gastroenterology practice for preliminary consultation about
1 week before colonoscopy. At that time, they were informed about
and invited to participate in the study and eligible patients
received a study package after informed consent. The study
package contained a collection tissue for avoiding contact of the
stool with toilet water, a small container and a plastic spoon for
stool collection (60ml), a plastic bag for storage of the container
and detailed instructions for stool collection. Stool from one bowel
movement was collected at home before bowel preparation for
colonoscopy without any specific recommendations for dietary or
medicinal restrictions. The stool was collected dry, that is without
buffer. Participants were asked to freeze or, if freezing was not
possible, to cool the stool sample. Less than 5% of participants
reported that freezing was not possible. On the day of colonoscopy,
participants rendered the stool-filled container at the gastroenter-
ological practice from where it was shipped on dry ice to a central
laboratory and frozen at  201C until analysis. The study package
also contained a standardised questionnaire, which the partici-
pants were asked to fill out. Among others, they were asked
about current use of specific medication, including analgesics and
low-dose aspirin.
After colonoscopy, we collected reports on colonoscopic and
histological findings and two independent, trained research
assistants extracted information in a standardised manner, while
blinded to the results of stool testing. As regards the increasingly
recognised subset of serrated polyps (Noffsinger, 2009), these
lesions were categorised according to the histological report into
adenomas or hyperplastic polyps. Colonoscopies as well as
histological examinations were also performed blinded to the
results of stool testing.
We thawed the stool-filled containers at a median interval of 4
days after arrival at the central laboratory to perform a
quantitative immunochemical FOBT. Faecal haemoglobin levels
were measured using an automated ELISA according to the
manufacturer’s instructions (RIDASCREEN Haemoglobin) (Haug
et al, 2010). The lower detection limit was 0.42mgg
–1 stool. All
analyses were done blinded to the results of colonoscopy.
The Ethics committees of the University of Heidelberg and of
the physicians’ chambers of Baden–Wu ¨rttemberg, Rheinland Pfalz
and Hessen approved the study.
Statistical analyses
As illustrated in Figure 1, we made the following consecutive
exclusions to ensure that study participants represent the average-
risk target population of CRC screening and to minimise potential
misclassification due to missed lesions on colonoscopy: visible
rectal bleeding or previous positive FOBT result (n¼157),
inflammatory bowel disease (n¼15), colonoscopy in the previous
5 years (n¼179), stool sampling after colonoscopy (n¼88),
incomplete colonoscopy (n¼37) and inadequate bowel preparation
for colonoscopy (n¼126). In addition, we excluded 91 participants
with pseudopolyps or histologically undefined polyps at screening
colonoscopy. Another 59 participants had to be excluded due to
missing of a suitable stool sample. Among the remaining 2325
participants potentially eligible to be included in the analyses, we
excluded 15 participants who were diagnosed with advanced
colorectal neoplasia both in the left and in the right colon.
Patients of screening colonoscopy volunteering to
participate (n = 3077)  
Participants eligible to receive study material
(n = 2920)
Exclusion due to incomplete colonoscopy (n = 37)
Exclusion due to visible rectal bleeding or previous
positive faecal occult blood test (n = 157)
Exclusion due to stool sampling after colonoscopy (n = 88)
Exclusion due to inadequate bowel preparation before
colonoscopy (n = 126)
Exclusion due to colonoscopy in the previous 5 years
(n = 179)
Exclusion of patients with pseudopolyps or histologically
non-defined polyps (n = 91)
Exclusion due to inflammatory bowel disease (n = 15)
Exclusion of patients without FOBT result (n = 59)
Exclusion of patient with advanced colorectal neoplasia
both in the left and in the right colon (n = 15)
Participants included in the analyses (n = 2310)
Patients with advanced
colorectal neoplasia
(n = 228)
Left-sided
(n = 157)
Right-sided
(n = 71)
Patients without advanced
colorectal neoplasia
(n = 2082)
Figure 1 Standards for reporting of diagnostic accuracy (STARD) flow
diagram.
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with advanced colorectal neoplasia (for calculation of sensitivity)
and the group of subjects without advanced colorectal neoplasia
(for calculation of specificity). Advanced colorectal neoplasia was
defined as CRC or an adenoma with at least one of the following
features: size X1cm, villous components or high-grade dysplasia.
For calculation of site-specific sensitivity, we categorised subjects
according to the location of the advanced colorectal neoplasia in
the right colon (including caecum, ascending colon, right flexure
and transverse colon) vs the left colon (including left flexure,
descending colon, sigmoid colon and rectum). To assess whether
there is a progressive increase in site-specific sensitivity going
from the right to the left side of the colon, we also calculated
sensitivities for a more detailed stratification according to
anatomical site.
We calculated sensitivities for left- and right-sided advanced
colorectal neoplasia and specificity at different cutoff levels (i.e.,
different threshold levels for test positivity) and calculated the
corresponding 95% confidence intervals (CIs) based on the exact
binomial distribution. We assessed the statistical significance of
differences in sensitivities between subjects with right- and left-
sided advanced colorectal neoplasia at clinically relevant cutoff
levels (i.e., cutoff levels yielding specificities that are typically
required in the screening setting) using two-sided w
2 tests with an
a level of 0.05.
To illustrate the discriminatory power of the test for advanced
colorectal neoplasia stratified by anatomical site (right- vs left-
sided), we constructed receiver-operating characteristic (ROC)
curves by plotting site-specific true positive rates (i.e., site-specific
sensitivities) against the corresponding false positive rates (i.e.,
100% specificity) for different cutoff levels. Each point on an ROC
curve thus represents a sensitivity/specificity pair corresponding
to a particular positivity threshold. We calculated the areas under
the ROC curves (AUCs) and the corresponding 95% CIs using the
method of DeLong et al (1988). The AUC is a measure of how well
a quantitative test can distinguish between subjects with and
without a disease.
To explore whether potential differences in site-specific test
performance may be due to an unequal distribution of other
factors that have been suggested to impact faecal haemoglobin
levels, such as sex, age, current NSAID use and the size and shape
of colorectal neoplasia (Ciatto et al, 2007; Morikawa et al, 2007;
Levi et al, 2009; Rozen et al, 2009), we compared the subgroups
with left- and right-sided advanced colorectal neoplasia regarding
these factors. Current NSAID use refers to individuals who
reported in the questionnaire that they are currently taking
analgesic or low doses of aspirin or other NSAIDs. We compared
median faecal haemoglobin levels for factors that could explain a
higher sensitivity for left-sided neoplasia according to their
distribution by site and used logistic regression analyses to assess
their association with the test sensitivity adjusted for site.
To explore further reasons that could result in different
diagnostic performance for left- and right-sided neoplasia, we
conducted sensitivity analyses, where we subset on individuals
with exactly one advanced colorectal neoplasm in either the left or
right colon and no other adenomas. This restriction removed a
potential source of heterogeneity between the subgroups with left-
and right-sided advanced neoplasia – other adenomas. Excluding
subjects with multiple adenomas eliminated interfering effects that
could result from more than one adenoma in the same individual
(such as a higher likelihood of bleeding due to plural occurrence of
adenomas). We constructed ROC curves stratified by anatomical
site and calculated AUCs and corresponding 95% CIs including
(1) only cases with one advanced colorectal neoplasm, (2) only
cases with one advanced adenoma (i.e., no CRC cases) and (3) only
cases with one large adenoma (X1cm).
In additional sensitivity analyses, we focused on subjects with
right-sided advanced colorectal neoplasia who did not have any
lesion in the left colon and we assessed whether there was a
difference in test performance in this restricted group compared
with the whole group of subjects with right-sided advanced
colorectal neoplasia.
We used MedCalc for Windows, version 9.6.4.0 (MedCalc
Software, Mariakerke, Belgium) for the ROC curves analyses and
SAS version 9.1 (SAS Institute Inc., Cary, NC) for all other
statistical analyses.
RESULTS
Overall, 2310 study participants were included in the analysis.
There were 157 and 71 subjects with advanced colorectal neoplasia
in the left and the right colon, respectively, and 2082 subjects
without advanced colorectal neoplasia (Figure 1).
Table 1 shows site-specific test performance of the immuno-
chemical FOBT at cutoff levels of 2, 4, 8 and 15 haemoglobin per g
stool, yielding specificities between 88% and 97%. At these levels of
specificity, sensitivity for left-sided advanced colorectal neoplasia
was 12–13 percentage points higher than for right-sided advanced
neoplasia. For example, at a specificity of 95%, corresponding with
a cutoff level of 8mg haemoglobin per g stool, sensitivity (95% CI)
for subjects with left- and right-sided advanced neoplasia was 33%
(26–41%) and 20% (11–31%), respectively (P¼0.04). A more
detailed anatomical stratification into caecum, ascending colon,
right to left flexure, descending to sigmoid colon and rectum
showed sensitivities (95% CI) of 13% (2–40%), 19% (6–38%), 26%
(9–51%), 35% (25–46%) and 23% (12–36%) at a specificity
of 95%.
Receiver-operating characteristic curves analysis showed that
sensitivities for detecting subjects with advanced neoplasia in the
left colon were higher compared with the right colon over the
whole range of specificities, that is at all cutoff levels (Figure 2).
The AUCs (95% CIs) were 0.71 (0.69–0.72) for the subgroup with
advanced neoplasia in the left colon and 0.60 (0.58–0.63) for the
subgroup with advanced neoplasia in the right colon. The
difference in site-specific AUCs did not change when CRC cases
were excluded from the analysis (Table 2).
A comparison of the diagnostic subgroups regarding factors that
might impact faecal haemoglobin levels is shown in Table 3. The
mean and median age was 65 years in participants with left- and
right-sided advanced neoplasia. The proportion of male partici-
pants and the proportion of current NSAID users were slightly
higher in the subgroup with right-sided advanced neoplasia than
in the subgroup with left-sided advanced neoplasia. The propor-
tion of subjects with large neoplasia (X1cm in diameter), the
proportion of subjects with more than one neoplasm, as well as the
proportion of subjects with more than one advanced neoplasm was
also higher in the subgroup with right-sided advanced neoplasia.
Table 1 Sensitivity and specificity of the immunochemical faecal occult
blood test for detecting individuals with left- vs right-sided advanced
colorectal neoplasia at different cutoff levels
Cutoff
level
(lgg
–1)
Specificity
(95% confidence
interval)
Sensitivity (95%
confidence interval)
P-value
(left-vs right-
sided)
Left-sided Right-sided
a
15 97% (96–98%) 26% (19–34%) 14% (7–24%) 0.04
8
a 95% (94–96%) 33% (26–41%) 20% (11–31%) 0.04
4 92% (90–93%) 38% (30–46%) 25% (16–37%) 0.07
2 88% (86–89%) 44% (36–52%) 30% (19–42%) 0.04
aAs described in Results section, sensitivity in this subgroup did not change when
restricting the analyses to the 60 subjects with right-sided advanced colorectal
neoplasia, who did not have any lesion in the left colon.
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adenomas was markedly higher in subjects with left- vs right-
sided advanced neoplasia (41 out of 88, corresponding to a
proportion of 0.47, vs 6 out of 42, corresponding to a proportion of
0.14). The median (interquartile range) faecal haemoglobin levels
were 3.3 (0.4–41.0) mgg
 1 in the 47 subjects with pedunculated
adenomas compared with 0.4 (o0.4–7.4) in the 83 subjects with
otherwise shaped adenomas, with the difference being statistically
significant (P¼0.02). Logistic regression analyses adjusted for site
showed a statistically significant association of pedunculated shape
with test sensitivity (P¼0.04).
Sensitivity analyses focusing on subjects with only one advanced
neoplasm (and no other adenomas) included 88 subjects with a
left-sided neoplasm and 35 subjects with a right-sided neoplasm.
The distribution of factors that may impact faecal haemoglobin
levels in this restricted study population was similar to the
distribution observed in the main analysis (Appendix). Figure 3
illustrates the ROC curves for detecting subjects with one advanced
colorectal neoplasm (and no other adenomas), stratified by left-
and right-sided location. While there was no clear difference at
higher levels of specificity, the ROC curves for right- and left-sided
advanced neoplasia diverged (towards higher sensitivities for left-
sided advanced neoplasia) starting at a specificity of about 87%,
which corresponds with a cutoff level of 2mg haemoglobin per g
stool. Again, the AUC was larger for the subgroup with one left-
sided advanced neoplasm than for the subgroup with one right-
sided advanced neoplasm and the difference persisted when
further exclusion criteria were applied to decrease heterogeneity
between subgroups with respect to the type and size of the
advanced neoplasm (Table 2).
In the subgroup of the 60 subjects with right-sided advanced
colorectal neoplasia who did not have any lesion in the left colon,
there was no difference in test performance compared with the
whole group of subjects with right-sided advanced colorectal
neoplasia (N¼71). Sensitivities were 22 and 20% in the former and
the latter group at a cutoff level of 8mgg
–1, and the AUCs were
0.60 and 0.61, respectively.
DISCUSSION
We extensively addressed the question of whether FOBT, the most
common non-invasive tool for CRC screening, shows differential
sensitivity for detecting left- vs right-sided advanced colorectal
neoplasia within a large screening study conducted in average-risk
subjects. Our analysis of data on an ELISA-based immunochemical
FOBT supports the hypothesis that FOBT is more sensitive for
detecting left-sided advanced neoplasia than right-sided advanced
neoplasia. The magnitude of the difference in sensitivities (about
13 percentage points) at a specificity of 95% is similar to the
findings reported by Morikawa et al (2005) regarding an
agglutination-based immunochemical FOBT (11) and is also
supported by another studies reporting on site-specific test
performance of a guaiac-based FOBT (Ahlquist et al, 2008).
However, the primary focus of the aforementioned studies was
on overall test performance; the authors did not provide further
information on the characteristics of the subgroups with left- and
right-sided advanced neoplasia. We focused, for the first time, on
this stratification according to anatomical site and explored
potential factors that could explain a higher sensitivity of FOBT
for left-sided neoplasia.
Specifically, we described the subgroups with left- and right-
sided advanced neoplasia with respect to parameters that were
reported to correlate with a higher sensitivity of FOBT, such as
male gender, current NSAID use and adenoma characteristics
(Ciatto et al, 2007; Morikawa et al, 2007; Levi et al, 2009; Rozen
et al, 2009). The proportion of men, the proportion of current
NSAID users, the proportion of subjects with large adenomas
(X1cm in diameter) as well as the proportion of subjects with
more than one adenoma was higher in the subgroup with right-
sided advanced neoplasia than in the subgroup with left-sided
advanced neoplasia. Thus, the distribution of these parameters
could not explain the observation of a higher sensitivity for left-
sided advanced neoplasia. In contrast, the proportion of subjects
with pedunculated adenomas was strikingly higher in the
subgroup with left-sided advanced neoplasia (0.47 vs 0.14).
Although information on adenoma shape was often missing, it is
unlikely that this difference is caused by information bias. The
latter would have occurred if the likelihood of reporting on
Table 2 Areas under the ROC) curves
a of the immunochemical faecal
occult blood test for detecting left- vs right-sided advanced colorectal
neoplasia
Diagnostic subgroup
Area under the ROC curve
a
(95% confidence interval)
Left-sided Right-sided
b
Advanced neoplasm(s) 0.71 (0.69–0.72) 0.60 (0.58–0.63)
Advanced adenoma(s) (no CRC) 0.69 (0.67–0.71) 0.60 (0.58–0.62)
Sensitivity analyses
c
One advanced neoplasm 0.67 (0.65–0.69) 0.61 (0.59–0.63)
One advanced adenoma (no CRC) 0.66 (0.64–0.68) 0.60 (0.58–0.62)
One large adenoma (X1cm) 0.71 (0.69–0.73) 0.66 (0.64–0.68)
Abbreviations: AUC¼area under the ROC curve; CRC¼colorectal cancer;
ROC¼receiver-operating characteristics.
aIn an ROC curve, the true positive rate
(sensitivity) is plotted in function of the false positive rate (100 specificity) for
different positivity thresholds (i.e., different cutoff levels) of a quantitative test (here,
faecal haemoglobin levels). The AUC is a measure of how well a quantitative test can
distinguish between subjects with and without a disease.
bAs described in Results
section, sensitivity in this subgroup did not change when restricting the analyses to the
60 subjects with right-sided advanced colorectal neoplasia who did not have any
lesion in the left colon.
cOnly individuals with one advanced colorectal neoplasm (and
no other adenomas) are included here as described in Materials and Methods section.
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Figure 2 ROC curves for detecting patients with advanced colorectal
neoplasia stratified by anatomical subsite, using a quantitative immuno-
chemical FOBT. (In an ROC curve, the true positive rate (sensitivity) is
plotted in function of the false positive rate (100 specificity) for different
positivity thresholds (i.e., different cutoff levels) of a quantitative test (here,
faecal haemoglobin levels). The AUC is a measure of how well a quantitative
test can distinguish between subjects with and without a disease.)
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spedunculated shape had been differential with respect to the
location of adenomas, which doesn’t seem plausible. The propor-
tion of participants for whom information on adenoma shape was
missing altogether was the same in the subgroup with left- and
right-sided advanced neoplasia. The higher proportion of pedun-
culated adenomas in the left colon is consistent with autopsy
studies that reported on the shape of adenomas according to
anatomical site (Blatt, 1961; Eide and Stalsberg, 1978; Rickert et al,
1979; Williams et al, 1982). The comparison of median faecal
haemoglobin levels in subjects with pedunculated adenomas vs
subjects with otherwise shaped adenomas as well as logistic
regression analyses adjusted for site supported the importance of
pedunculated shape regarding the site difference in test sensitivity.
The proportion of CRC cases was also higher in the subgroup
with left-sided neoplasia, but the respective numbers were small
and their exclusion did not change the observed differences in
site-specific test performance.
In the primary analysis of ROC curves, we observed a higher
sensitivity for individuals with left-sided advanced neoplasia at all
cutoff levels, including cutoff levels yielding specificities that are
typically required in the screening setting (i.e., well above 90%). In
sensitivity analysis, we explored whether the difference in
sensitivities according to anatomical site was due to the location
of the advanced neoplasm itself. For that purpose, we restricted the
analyses of ROC curves to individuals with one advanced
colorectal neoplasm and no other adenomas. Even though this
restriction created an artificial setting that does not reflect the
distribution of neoplasms in the natural setting, it avoided
interfering effects that could result from more than one adenoma
in the same individual, which are potentially distributed over
different anatomical sites. Interestingly, the difference in diag-
nostic performance according to anatomical site in this restricted
setting occurred only when sensitivity was increased by shifting
the cutoff level to lower levels (i.e., lower specificity), but was not
observed at higher, clinically relevant cutoff levels (i.e., at levels
yielding specificities well above 90%). This finding could be
interpreted as follows: when the cutoff level is high, which means
that only individuals with a relatively strong source of bleeding test
positive, it doesn’t matter whether the advanced neoplasm is in the
right or in the left colon. When the cutoff level is lowered, which
allows individuals with a weaker source of bleeding to test positive
as well, then sensitivity is higher for left-sided than for right-sided
advanced neoplasia. In other words, our results suggest that weak
sources of bleeding are more likely to occur (possibly due to
pedunculated shape of adenomas) or to be detected (possibly due
to degradation of haemoglobin) in the left colon than in the right
colon, while the location doesn’t matter when there is a strong
source of bleeding.
An explanatory model that synthesises the different findings
could be as follows: a certain proportion of advanced neoplasms
present by themselves a relatively strong source of bleeding and
their likelihood of being detected through FOBT does not depend
on the anatomical site. Another proportion of advanced neoplasms
is weak sources of bleeding and do not lead by themselves to a
positive FOBT at clinically relevant cutoff levels. However, in
conjunction with other adenomas, which may also represent weak
sources of bleeding, haemoglobin levels may mount up leading to a
positive FOBT at clinically relevant cutoff levels (i.e., at levels
yielding specificities well above 90%). This additive mechanism
may cause the higher sensitivity for left-sided neoplasia at
clinically relevant cutoff levels since our findings suggested that
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Figure 3 ROC curves for detecting patients with one advanced
colorectal neoplasm (and no other colorectal adenomas) stratified by
anatomical subsite, using a quantitative immunochemical FOBT. (In an ROC
curve, the true positive rate (sensitivity) is plotted in function of the false
positive rate (100 specificity) for different positivity thresholds (i.e.,
different cutoff levels) of a quantitative test (here, faecal haemoglobin
levels). The AUC is a measure of how well a quantitative test can
distinguish between subjects with and without a disease.)
Table 3 Comparison of the diagnostic subgroups with respect to factors that have been suggested to potentially impact faecal haemoglobin levels
Subjects with advanced
colorectal neoplasia
a
Left-sided
(N¼157)
Right-sided
(N¼71)
Subjects without advanced
colorectal neoplasia (N¼2082)
Mean age (years) 65 65 62
Median age (years) (interquartile range) 65 (59–70) 65 (59–69) 61 (57–67)
Proportion men 0.62 0.65 0.48
Proportion current NSAID users
b 0.12 0.17 0.15
Proportion subjects with neoplasm(s) X1cm 0.68 0.76 N.a.
Proportion subjects with more than one neoplasm 0.44 0.51 N.a.
Proportion subjects with more than one advanced neoplasm 0.12 0.14 N.a.
Proportion subjects with pedunculated adenoma(s)
c 0.47 0.14 N.a.
Proportion with CRC 0.08 0.01 N.a.
Abbreviations: CRC¼colorectal cancer; N.a.¼not applicable; NSAID¼non-steroidal anti-inflammatory drugs.
aDefined as CRC or adenoma X1cm in size, adenomas with
villous components or adenomas with high-grade dysplasia.
bAs described in Materials and Methods section, this variable also includes users of low-dose aspirin.
cWe only
considered subjects for whom information on shape was reported for all adenomas that were detected at colonoscopy; the percentages thus refer to 88 subjects with left-sided
neoplasm(s) and 42 subjects with right-sided neoplasm(s).
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more likely in the left colon than in the right colon.
Irrespective of the reasons explaining the higher sensitivity of
FOBT for left-sided advanced neoplasia, the finding itself would be
of clinical relevance. While colonoscopy has already been
questioned regarding protection from right-sided colorectal
neoplasia (Brenner et al, 2007, 2010b; Lakoff et al, 2008; Baxter
et al, 2009), our study supports the hypothesis that FOBT, the most
common non-invasive tool for CRC screening, also shows lower
performance for right-sided neoplasia. Our findings may stimulate
further diagnostic research in the field. They may also provide
valuable information for modelling analyses to estimate the
potential effects of site-specific test performance on the program-
matic sensitivity and the effectiveness of FOBT-based screening
programmes in which FOBT is repeated at frequent intervals (e.g.,
annually or biennially). In particular, current strategies that
combine flexible sigmoidoscopy and FOBT could be affected by
a lower sensitivity of FOBT for right-sided lesions (Pignone et al,
2002; Zauber et al, 2008). Such strategies have been suggested to be
as effective as colonoscopy in some scenarios, but those findings
might change if site-specific test performance of FOBT is taken
into account. Generally, site-specific performance should be a
focus in the optimisation of current screening tests as well as in the
development and evaluation of novel screening tests, such as
computed tomographic colonography (Heresbach et al, 2011) and
colon capsule endoscopy (Sacher-Huvelin et al, 2010).
Our study offered good opportunity for evaluating site-specific
test performance due to the fact that all study participants
underwent colonoscopy irrespective of the FOBT result and due to
a setting that reflects the average-risk target population of CRC
screening. Using a symptomatic study population or using a
clinical follow-up instead of colonoscopy to estimate diagnostic
performance could bias site-specific estimates of test sensitivity
since the presence of symptoms or the likelihood of clinical
manifestation may depend on anatomical site. The prospective
design, the careful application of exclusion criteria as well as the
high level of experience and qualification among gastroenterologist
who participate in the German screening colonoscopy programme
were favourable in terms of minimising potential sources of bias.
Our study has also important limitations. First, the group with
‘advanced neoplasia’ was comprised for the most part individuals
with advanced adenomas, while the number of individuals with
CRC was low. Given that advanced adenomas are considered to be
precursors to CRC, our results thus support site-specific effects
with respect to prevention from CRC through FOBT. To investigate
whether there are also site-specific effects with respect to early
detection of invasive CRC, very large sample sizes would be needed
since the prevalence of undetected CRC is inherently low in an
average-risk study population. From a theoretical point of view,
site-specific effects might be less important for invasive CRCs,
which, if they bleed, have been reported to go along with
comparatively high faecal haemoglobin levels (Levi et al, 2007).
Second, although we had a reasonable sample size of participants
with advanced neoplasia, further stratification according to
parameters that have been suggested to impact faecal haemoglobin
levels and calculation of site-specific test performance for each of
the subgroups would not have been possible due to sample size
limitations. We, therefore, only assessed whether these parameters
were differentially distributed across the subgroups with left- and
right-sided advanced colorectal neoplasia. There were also sample
size limitations regarding the more detailed stratification of
sensitivities according to anatomical site. Although the point
estimates of these analyses tentatively suggest a progressive
increase in sensitivity from the right to the left side of the colon
(excluding the rectum), the CIs of these estimates were large. The
comparatively low sensitivity for rectal lesions could be due to the
exclusion criterion ‘visual bleeding’, which may apply more often
to subjects with rectal neoplasms that bleed than to subjects with
neoplasms at other parts of the colon (where it may be less likely
that the blood is detected visually). Third, it would be interesting
to investigate whether site-specific test performance is affected by
the number of stool samples that are tested per person or by
different sampling techniques, which, however, we could not assess
in our study.
We did not consider site-specific performance of FOBT with
respect to any adenoma, but focused on advanced adenomas
because they are considered to be the most clinically relevant
precursor lesions. This focus also minimised potential misclassi-
fication bias due to miss rates at colonoscopy, which may be site
specific, but which have been shown to be generally low for
advanced neoplasia (van Rijn et al, 2006; Heresbach et al, 2008).
In conclusion, the immunochemical FOBT in our study was
more sensitive for detecting subjects with left- vs right-sided
advanced colorectal neoplasia. Our findings may stimulate further
research in the field as well as modelling analyses to estimate the
potential effect of site-specific test performance on the program-
matic sensitivity and the effectiveness of annual or biennial FOBT-
based screening programmes, in particular with respect to
protection from right-sided CRC.
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Appendix
Subjects with one advanced
colorectal neoplasm
a
Left-sided
(N¼88)
Right-sided
(N¼35)
Subjects without advanced colorectal
neoplasia (N¼2082)
Mean age (years) 64 65 62
Median age (years) (interquartile range) 64 (58–69) 65 (59–70) 61 (57–67)
Proportion men 0.56 0.63 0.48
Proportion current NSAID users
b 0.11 0.29 0.15
Proportion subjects with neoplasm(s) X1cm 0.60 0.77 N.a.
Proportion subjects with more than one neoplasm N.a. N.a. N.a.
Proportion subjects with more than one advanced neoplasm N.a. N.a. N.a.
Proportion subjects with pedunculated adenoma(s)
c 0.48 0.07 N.a.
Proportion with CRC 0.06 0.03 N.a.
Abbreviations: CRC¼colorectal cancer; N.a.¼not applicable; NSAID¼non-steroidal anti-inflammatory drugs.
aDefined as CRC or adenoma X1cm in size, adenomas with
villous components or adenomas with high-grade dysplasia; only individuals with one advanced colorectal neoplasm (and no other adenomas) are included here as described in
Materials and Methods section.
bAs described in Materials and Methods section, this variable also includes users of low-dose aspirin.
cInformation on shape was reported for 62
subjects with a left-sided neoplasm and 27 subjects with a right-sided neoplasm. The percentages refer to these subjects.
Table A1 Comparison of the diagnostic subgroups with respect to factors that have been suggested to potentially impact faecal haemoglobin levels for
subjects who were included in the sensitivity analyses
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